The use of B-type natriuretic peptide in the management of patients with diabetes and acute dyspnoea

Springer Science and Business Media LLC - Tập 49 - Trang 629-636 - 2006
C. Mueller1, K. Laule-Kilian1, A. Christ1, A. P. Perruchoud1
1Department of Internal Medicine, University Hospital, Basel, Switzerland

Tóm tắt

The aim of this study was to determine the impact of measurement of B-type natriuretic peptide (BNP) levels on the management of patients with diabetes presenting with acute dyspnoea. This study evaluated the subgroup of 103 patients with diabetes included in the B-type Natriuretic Peptide for Acute Shortness of Breath Evaluation (BASEL) study (n=452). Patients were randomly assigned to a diagnostic strategy with (n=47, BNP group) or without (n=56, control group) the use of BNP levels assessed by a rapid bedside assay. Time to discharge and total cost of treatment were recorded as the primary endpoints. Although similar with regard to age and sex, patients with diabetes more often had pre-existing cardiovascular and renal disease and heart failure as the cause of acute dyspnoea compared with patients without diabetes. In addition, medical and economic outcomes were worse in patients with diabetes. The use of BNP levels significantly reduced time to discharge (median 9 days [interquartile range (IQR) 2–16] in the BNP group vs 13 days [IQR 8–22] in the control group; p=0.016). At 30 days, the diabetic patients in the BNP group had spent significantly fewer days in hospital compared with the diabetic patients in the control group (9 days [IQR 2–19] vs 16 days [IQR 8–24], respectively; p=0.008). Total treatment costs at 30 days were US$5,705 (IQR 2,285–9,137) in the BNP group and US$7,420 (IQR 4,194–11,966) in the control group (p=0.036). The results of this study indicate that measurement of BNP levels improves the management of patients with diabetes presenting with acute dyspnoea.

Tài liệu tham khảo

Hunt SA, Baker DW, Chin MH et al (2001) ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 104:2996–3007

Remme WJ, Swedberg K (2001) Guidelines for the diagnosis and treatment of chronic heart failure. Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology. Eur Heart J 22:1527–1560

American Thoracic Society (1999) Dyspnea. Mechanisms, assessment, and management: a consensus statement Am J Respir Crit Care Med 159:321–340

American Heart Association (2003) Heart disease and stroke statistics, update. American Heart Association, Dallas, 2002

Bales AC, Sorrentino MJ (1997) Causes of congestive heart failure: prompt diagnosis may affect prognosis. Postgrad Med 101:44–49, 54–56

Wuerz RC, Meador SA (1992) Effects of prehospital medications on mortality and length of stay in congestive heart failure. Ann Emerg Med 21:669–674

Kannel WB, Hjortland M, Castelli WP (1974) Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 34:29–34

Devereux RB, Roman MJ, Paranicas M et al (2000) Impact of diabetes on cardiac structure and function: the Strong Heart Study. Circulation 101:2271–2276

Spector KS (1998) Diabetic cardiomyopathy. Clin Cardiol 21:885–887

Bell DSH (2003) Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 26:2433–2441

Bell DSH (2004) Heart failure: a serious and common comorbidity of diabetes. Clin Diabetes 22:61–65

Redfield MM, Jacobsen SJ, Burnett JC, Mahoney DW, Bailey KR, Rodeheffer RJ (2003) Burden of systolic and diastolic ventricular dysfunction in the community. JAMA 289:194–202

Poirier P, Bogaty P, Garneau C, Marois L, Dumesnil JG (2001) Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes. Importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care 24:5–10

Maisel AS, Krishnaswamy P, Nowak RM et al (2002) Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347:161–167

Davis M, Espiner E, Richards G et al (1994) Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet 343:440–444

Maisel AS, McCord J, Nowak RM et al (2003) Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction: results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol 41:2010–2017

McCullough PA, Duc P, Omland T et al (2003) B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 41:571–579

Mueller C, Laule Kilian K, Scholer A et al (2005) B-type natriuretic peptide for acute dyspnea in patients with kidney disease: insights from a randomized comparison. Kidney Int 67:278–284

Mueller C, McHodgson JB, Brutsche M et al (2002) Impact of intracoronary ultrasound guidance on long-term outcome of percutaneous coronary interventions in diabetics—insights from the randomized SIPS trial. Swiss Med Wkly 132:279–284

Mueller C, Neumann FJ, Ferenc M, Perruchoud AP, Buettner HJ (2004) Impact of diabetes mellitus on long-term outcome after unstable angina and non-ST-segment elevation myocardial infarction treated with very early revascularisation. Diabetologia 47:1188–1195

Wright SP, Doughty RN, Pearl A et al (2003) Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care. A randomized, controlled trial. J Am Coll Cardiol 42:1793–1800

Mueller C, Scholer A, Laule Kilian K et al (2004) Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 350:647–654

Cheng V, Kazanagra R, Garcia A et al (2001) A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 37:386–391

Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB, for the Panel on Cost-Effectiveness in Heath and Medicine (1996) Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 276:1253–1258

Siegel JE, Weinstein MC, Russell LB, Gold MR, for the Panel on Cost-Effectiveness in Heath and Medicine (1996) Recommendations for reporting cost-effectiveness analysis. JAMA 276:1339–1341

Yano Y, Katsuki A, Gabazza EC et al (1999) Plasma brain natriuretic peptide levels in normotensive noninsulin-dependent diabetic patients with microalbuminuria. J Clin Endocrinol Metab 84:2353–2356

Epshteyn V, Morrison K, Krishnaswamy P et al (2003) Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. Diabetes Care 26:2081–2087

Nagai T, Imamura M, Inukai T, Mori M (2001) Brain natriuretic polypeptide in type 2 NIDDM patients with albuminuria. J Med 32:169–180

Wu AHB, Omland T, Duc P et al (2004) The effect of diabetes on B-type natriuretic peptide concentrations in patients with acute dyspnea. Diabetes Care 2398–2404

Wang TJ, Larson MG, Levy D et al (2004) Impact of obesity on plasma natriuretic peptide levels. Circulation 109:594–600

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Tập 49

629-636

Thông tin tác giả